Literature DB >> 27880950

Protease-Activated Receptor 1 Contributes to Angiotensin II-Induced Cardiovascular Remodeling and Inflammation.

Silvio Antoniak1, Jessica C Cardenas, Laura J Buczek, Frank C Church, Nigel Mackman, Rafal Pawlinski.   

Abstract

BACKGROUND: Angiotensin II (Ang II) plays an important role in cardiovascular disease. It also leads to the activation of coagulation. The coagulation protease thrombin induces cellular responses by activating protease-activated receptor 1 (PAR-1). We investigated whether PAR-1 contributes to Ang II-induced cardiovascular remodeling and inflammation. METHODS AND
RESULTS: PAR-1+/+ (wild-type; WT) and PAR-1-/- mice were infused with Ang II (600 ng/kg/min) for up to 4 weeks. In WT mice, this dose of Ang II did not cause a significant increase in blood pressure but it did cause pathological changes in both the aorta and the heart. Ang II infusion resulted in vascular remodeling of the aorta, demonstrated by a significant increase in medial wall thickening and perivascular fibrosis. Importantly, both parameters were significantly attenuated by PAR-1 deficiency. Furthermore, perivascular fibrosis around coronary vessels was reduced in Ang II-treated PAR-1-/- mice compared to WT mice. In addition, PAR-1 deficiency significantly attenuated Ang II induction of inflammatory cytokines and profibrotic genes in the aortas compared to WT mice. Finally, PAR-1 deficiency had no effect on Ang II-induced heart hypertrophy. However, the heart function measured by fractional shortening was less impaired in PAR-1-/- mice than in WT mice.
CONCLUSION: Our data indicate that PAR-1 plays a significant role in cardiovascular remodeling mediated by a blood pressure-independent action of Ang II.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27880950      PMCID: PMC5334284          DOI: 10.1159/000452269

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  71 in total

1.  Effects of normal blood pressure, prehypertension, and hypertension on coronary microvascular function.

Authors:  Dogan Erdogan; Ibrahim Yildirim; Ozgur Ciftci; Ismail Ozer; Mustafa Caliskan; Hakan Gullu; Haldun Muderrisoglu
Journal:  Circulation       Date:  2007-02-06       Impact factor: 29.690

Review 2.  Extracellular mediators in atherosclerosis and thrombosis: lessons from thrombin receptor knockout mice.

Authors:  Christopher D Major; Rosemary J Santulli; Claudia K Derian; Patricia Andrade-Gordon
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-04-03       Impact factor: 8.311

3.  Administration of a potent antagonist of protease-activated receptor-1 (PAR-1) attenuates vascular restenosis following balloon angioplasty in rats.

Authors:  P Andrade-Gordon; C K Derian; B E Maryanoff; H C Zhang; M F Addo; B P Damiano; M R D'Andrea; A L Darrow; L de Garavilla; A J Eckardt; E C Giardino; B J Haertlein; D F McComsey
Journal:  J Pharmacol Exp Ther       Date:  2001-07       Impact factor: 4.030

4.  Angiotensin II (AT(1)) receptor blockade reduces vascular tissue factor in angiotensin II-induced cardiac vasculopathy.

Authors:  D N Müller; E M Mervaala; R Dechend; A Fiebeler; J K Park; F Schmidt; J Theuer; V Breu; N Mackman; T Luther; W Schneider; D Gulba; D Ganten; H Haller; F C Luft
Journal:  Am J Pathol       Date:  2000-07       Impact factor: 4.307

5.  Myocardial fibrosis and diastolic dysfunction in patients with hypertension: results from the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).

Authors:  Richard Müller-Brunotte; Thomas Kahan; Begoña López; Magnus Edner; Arantxa González; Javier Díez; Karin Malmqvist
Journal:  J Hypertens       Date:  2007-09       Impact factor: 4.844

6.  Cardiac hypertrophy-induced changes in mRNA levels for TGF-beta 1, fibronectin, and collagen.

Authors:  F J Villarreal; W H Dillmann
Journal:  Am J Physiol       Date:  1992-06

7.  Early left ventricular mechanics abnormalities in prehypertension: a two-dimensional strain echocardiography study.

Authors:  Vitantonio Di Bello; Enrica Talini; Giulia Dell'Omo; Cristina Giannini; Maria Grazia Delle Donne; Maria Laura Canale; Carmela Nardi; Caterina Palagi; Frank Lloyd Dini; Giuseppe Penno; Stefano Del Prato; Mario Marzilli; Roberto Pedrinelli
Journal:  Am J Hypertens       Date:  2009-12-31       Impact factor: 2.689

8.  Early impairment of coronary flow reserve in young men with borderline hypertension.

Authors:  H Laine; O T Raitakari; H Niinikoski; O P Pitkänen; H Iida; J Viikari; P Nuutila; J Knuuti
Journal:  J Am Coll Cardiol       Date:  1998-07       Impact factor: 24.094

9.  Immunity, Inflammation, and Prehypertension: In What Order?

Authors:  Arthur Sá Ferreira
Journal:  J Clin Hypertens (Greenwich)       Date:  2015-07-03       Impact factor: 3.738

10.  Role of chemokine RANTES in the regulation of perivascular inflammation, T-cell accumulation, and vascular dysfunction in hypertension.

Authors:  Tomasz P Mikolajczyk; Ryszard Nosalski; Piotr Szczepaniak; Klaudia Budzyn; Grzegorz Osmenda; Dominik Skiba; Agnieszka Sagan; Jing Wu; Antony Vinh; Paul J Marvar; Bartlomiej Guzik; Jakub Podolec; Grant Drummond; Heinrich E Lob; David G Harrison; Tomasz J Guzik
Journal:  FASEB J       Date:  2016-02-12       Impact factor: 5.191

View more
  14 in total

1.  Noncanonical Matrix Metalloprotease 1-Protease-Activated Receptor 1 Signaling Drives Progression of Atherosclerosis.

Authors:  Rajashree Rana; Tianfang Huang; Georgios Koukos; Elizabeth K Fletcher; Susan E Turner; Andrew Shearer; Paul A Gurbel; Jeffrey J Rade; Carey D Kimmelstiel; Kevin P Bliden; Lidija Covic; Athan Kuliopulos
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-04-05       Impact factor: 8.311

2.  Protease-activated receptor 1 activation enhances doxorubicin-induced cardiotoxicity.

Authors:  Silvio Antoniak; Kohei Tatsumi; Clare M Schmedes; Steven P Grover; Rafal Pawlinski; Nigel Mackman
Journal:  J Mol Cell Cardiol       Date:  2018-08-10       Impact factor: 5.000

Review 3.  The multifaceted role of fibrinogen in tissue injury and inflammation.

Authors:  James P Luyendyk; Jonathan G Schoenecker; Matthew J Flick
Journal:  Blood       Date:  2018-12-06       Impact factor: 22.113

4.  Serum protease-activated receptor (PAR-1) levels as a potential biomarker for diagnosis of inflammation in type 2 diabetic patients.

Authors:  Sanjay Goyal; Ankita Sood; Isha Gautam; Soumyadip Pradhan; Puskar Mondal; Gaaminepreet Singh; Ravinder Singh Jaura; Thakur Gurjeet Singh; Raminderpal Singh Sibia
Journal:  Inflammopharmacology       Date:  2022-08-16       Impact factor: 5.093

5.  Enhanced Thrombin Generation Is Associated with Worse Left Ventricular Scarring after ST-Segment Elevation Myocardial Infarction: A Cohort Study.

Authors:  Ching-Hui Sia; Sock-Hwee Tan; Siew-Pang Chan; Stephanie Marchesseau; Hui-Wen Sim; Leonardo Carvalho; Ruth Chen; Nor Hanim Mohd Amin; Alan Yean-Yip Fong; Arthur Mark Richards; Christina Yip; Mark Y Chan
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-06

6.  Plasma C4 level was associated with mortality, cardiovascular and cerebrovascular complications in hemodialysis patients.

Authors:  Zheyu Xing; Yaqin Wang; Kunjing Gong; Yuqing Chen
Journal:  BMC Nephrol       Date:  2022-06-29       Impact factor: 2.585

7.  Cell type-specific mechanisms coupling protease-activated receptor-1 to infectious colitis pathogenesis.

Authors:  Alexander A Boucher; Leah Rosenfeldt; Duaa Mureb; Jessica Shafer; Bal Krishan Sharma; Adam Lane; Rebecca R Crowther; Melanie C McKell; Jordan Whitt; Theresa Alenghat; Joseph Qualls; Silvio Antoniak; Nigel Mackman; Matthew J Flick; Kris A Steinbrecher; Joseph S Palumbo
Journal:  J Thromb Haemost       Date:  2019-10-11       Impact factor: 5.824

8.  Anticoagulation increases alveolar hemorrhage in mice infected with influenza A.

Authors:  Kohei Tatsumi; Silvio Antoniak; Saravanan Subramaniam; Bertrand Gondouin; Scott D Neidich; Melinda A Beck; Jacqueline Mickelson; Dougald M Monroe; Julie A Bastarache; Nigel Mackman
Journal:  Physiol Rep       Date:  2016-12

9.  Blockade of PAR-1 Signaling Attenuates Cardiac Hypertrophy and Fibrosis in Renin-Overexpressing Hypertensive Mice.

Authors:  Yoshikazu Yokono; Kenji Hanada; Masato Narita; Yota Tatara; Yousuke Kawamura; Naotake Miura; Kazutaka Kitayama; Masamichi Nakata; Masashi Nozaka; Tomo Kato; Natsumi Kudo; Michiko Tsushima; Yuichi Toyama; Ken Itoh; Hirofumi Tomita
Journal:  J Am Heart Assoc       Date:  2020-06-04       Impact factor: 5.501

10.  Cell type-specific roles of PAR1 in Coxsackievirus B3 infection.

Authors:  Michael F Bode; Clare M Schmedes; Grant J Egnatz; Vanthana Bharathi; Yohei M Hisada; David Martinez; Tomohiro Kawano; Alice Weithauser; Leah Rosenfeldt; Ursula Rauch; Joseph S Palumbo; Silvio Antoniak; Nigel Mackman
Journal:  Sci Rep       Date:  2021-07-12       Impact factor: 4.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.